Darapladib is a Potent Lp-PLA2 Inhibitor for Atherosclerosis and Cancer Research
Darapladib is an orally active, selective and reversible Lp-PLA2 inhibitor, with an IC50 value of 0.25 nM.
Darapladib is an orally active, selective and reversible Lp-PLA2 inhibitor, with an IC50 value of 0.25 nM.
Darapladib (SB-480848) is a potent, selective, freely reversible, non-covalently bound, orally active inhibitor of Lp-PLA2 with an IC50 of 0.25 nM, and it serves as a predictive biomarker of inflammation in cardiovascular…